Evaluation of Interleukin- 5 in Mild and Moderate Asthmatic Patients Following Corticosteroid Therapy

Abstract

Background: Asthma is a very common chronic disease in Iraqi community.
 Involving the respiratory system in which the airways occasionally constrict, become
 inflamed, and are lined with excessive amounts of mucus often in response to one or
 more triggers.
 Aim: this study was conducted to determine the role of interleukin 5 as asthmatic
 biomarker in Iraqi community in order to target the trait.
 Patients and Methods: Serum level of interleukin-5 [SIL-5] which is one of the
 inflammatory markers in asthma was estimated in 90 persons including those with
 asthma on steroid therapy (35 patients) and those without steroid (35 patients)
 therapy and the healthy control group (20 persons).
 Results: The mean level of SIL-5 was high in moderate asthmatic patients without
 steroid in their treatment protocol (16.56 pg/ml), while it was less in mild asthmatic
 patients without steroid therapy. SIL-5 mean values were lower in mild and moderate
 asthmatic patients who receive steroid therapy (3.94 pg/ml, 4.10 pg/ml respectively).
 While it was least in the control healthy group (3.32 pg/ml).
 Conclusion: serum IL-5 is predictive biomarkers for asthma severity and
 treatment response monitoring in Iraqi subjects with asthma